Research in anxiety disorders: from the bench to the bedside
Research in anxiety disorders: from the bench to the bedside
The development of ethologically based behavioural animal models has clarified the
anxiolytic properties of a range of neurotransmitter and neuropeptide receptor agonists and
antagonists, with several models predicting efficacy in human clinical samples.
Neuro-cognitive models of human anxiety and findings from fMRI suggest dysfunction in amygdalaprefrontal
circuitry underlies biases in emotion activation and regulation. Cognitive and neural
mechanisms involved in emotion processing can be manipulated pharmacologically, and research
continues to identify genetic polymorphisms and interactions with environmental risk factors that
co-vary with anxiety-related behaviour and neuro-cognitive endophenotypes.
This paper describes findings from a range of research strategies in anxiety, discussed at the
recent ECNP Targeted Expert Meeting on anxiety disorders and anxiolytic drugs. The efficacy of
existing pharmacological treatments for anxiety disorders is discussed, with particular reference to
drugs modulating serotonergic, noradrenergic and gabaergic mechanisms, and novel targets
including glutamate, CCK, NPY, adenosine and AVP. Clinical and neurobiological predictors of
active treatment and placebo response are considered.
anxiety, treatment, imaging, cognition
381-390
Garner, Matthew
3221c5b3-b951-4fec-b456-ec449e4ce072
Möhler, Hanns
51c40d69-5d27-4272-a9f9-e212ce1b4838
Stein, Dan J.
07cf0cbd-837d-49ac-aceb-1c393a2f3e00
Mueggler, Thomas
e8067958-b34d-4fb0-b2e2-b6ed94b12b6f
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
1 June 2009
Garner, Matthew
3221c5b3-b951-4fec-b456-ec449e4ce072
Möhler, Hanns
51c40d69-5d27-4272-a9f9-e212ce1b4838
Stein, Dan J.
07cf0cbd-837d-49ac-aceb-1c393a2f3e00
Mueggler, Thomas
e8067958-b34d-4fb0-b2e2-b6ed94b12b6f
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Garner, Matthew, Möhler, Hanns, Stein, Dan J., Mueggler, Thomas and Baldwin, David S.
(2009)
Research in anxiety disorders: from the bench to the bedside.
European Neuropsychopharmacology, 19 (6), .
(doi:10.1016/j.euroneuro.2009.01.011).
Abstract
The development of ethologically based behavioural animal models has clarified the
anxiolytic properties of a range of neurotransmitter and neuropeptide receptor agonists and
antagonists, with several models predicting efficacy in human clinical samples.
Neuro-cognitive models of human anxiety and findings from fMRI suggest dysfunction in amygdalaprefrontal
circuitry underlies biases in emotion activation and regulation. Cognitive and neural
mechanisms involved in emotion processing can be manipulated pharmacologically, and research
continues to identify genetic polymorphisms and interactions with environmental risk factors that
co-vary with anxiety-related behaviour and neuro-cognitive endophenotypes.
This paper describes findings from a range of research strategies in anxiety, discussed at the
recent ECNP Targeted Expert Meeting on anxiety disorders and anxiolytic drugs. The efficacy of
existing pharmacological treatments for anxiety disorders is discussed, with particular reference to
drugs modulating serotonergic, noradrenergic and gabaergic mechanisms, and novel targets
including glutamate, CCK, NPY, adenosine and AVP. Clinical and neurobiological predictors of
active treatment and placebo response are considered.
This record has no associated files available for download.
More information
Submitted date: 5 January 2009
Published date: 1 June 2009
Keywords:
anxiety, treatment, imaging, cognition
Identifiers
Local EPrints ID: 66749
URI: http://eprints.soton.ac.uk/id/eprint/66749
ISSN: 0924-977X
PURE UUID: eb1bdfa4-1472-4bb0-b5ec-6a77f8c8ffb1
Catalogue record
Date deposited: 16 Jul 2009
Last modified: 14 Mar 2024 02:46
Export record
Altmetrics
Contributors
Author:
Hanns Möhler
Author:
Dan J. Stein
Author:
Thomas Mueggler
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics